drugset
drugset / Trial / NCT01091142

Single-Ascending-Dose Safety/Tolerability of NP001 in Amyotrophic Lateral Sclerosis (ALS)

NCT01091142 ↗

Phase 1 Completed 56 enrolled Neuraltus Pharmaceuticals, Inc.
RandomizedParallel-groupQuadruple-blindTreatment

Summary

Primary objectives: To assess the safety and tolerability of ascending doses of NP001 compared to placebo in subjects with ALS. Secondary objective: To explore the effects of NP001 on biomarkers potentially relevant to ALS.

Timeline

Start
2010-07
Primary completion
2010-09
Completion
—

Drugs

EvaluationDrugModalityDoseRoute
Subject NP001 Unknown 0.3 mg/kg —
Subject NP001 Unknown 1.1 mg/kg —
Subject NP001 Unknown 2.1 mg/kg —
Subject NP001 Unknown 4.3 mg/kg —

Indications

amyotrophic lateral sclerosis